Menu
Not yet recruiting NCT07601152

Clinical and Biological Study of Early-onset Breast Cancer and the Influence of the Reproductive Cycle on the Aggressiveness of the Disease

Observational Breast Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: No Intervention: Observational Cohort.
Who it may be relevant to
Registry conditions: Breast Cancer. Basic parameters: up to 45 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The incidence of breast cancer is increasing, particularly among young women. Cancers in young women are associated with a poor prognosis. The causes remain poorly understood. Among young patients, some are nulliparous and others have reported cancer during or after pregnancy. Preliminary studies suggest that breast tissue remodeling associated with pregnancy may influence the emergence and aggressiveness of early-onset cancers. However, breastfeeding and pregnancy are described as protective factors against the onset of breast cancer. The precise biology depending on age and the time between pregnancy and breast cancer is still poorly understood. The aim of our study is to increase our knowledge of cancer in young women and its potential links to pregnancy and breastfeeding. Information on the contraceptive habits and pregnancies of the patients in the study will be collected, and molecular and cellular analyses will be performed on frozen tumor samples as well as samples fixed and embedded in paraffin.

Interventions

  • Other No Intervention: Observational Cohort
    No intervention

Primary outcome measures

  • event-free survival [Time frame: up to 5 years]
Secondary outcome measures (4)
  • Describe the association between age at diagnosis and event-free survival (EFS) and overall survival. [Time frame: up to 5 years]
  • Describe the association between previous pregnancy and overall survival according to age at diagnosis (≤45 years or ≥55 years). [Time frame: Up to 5 years]
  • Describe the association between breastfeeding and EFS/overall survival in nulliparous women according to age at diagnosis (≤45 years or ≥55 years). [Time frame: Up to 5 years]
  • Describe the association between age at first pregnancy (≥35 years, ≤35 years, nulliparity) and EFS/overall survival according to age at diagnosis (≤45 years or ≥55 years). [Time frame: Up to 5 years]

Eligibility criteria

Inclusion criteria

  • Triple-negative breast cancer or RH+/HER2-
  • Patient aged ≤ 45 years at the time of diagnosis ou Patient aged ≥ 55 years at the time of diagnosis

Exclusion criteria

  • Availability of a diagnostic tumor sample

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

France · 1 center
  • Institut de Cancerologie de L'Ouest — Saint-Herblain

Identifiers

NCT: NCT07601152 · ICO-2024-25 · 2025-A02135-4

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗